- Home
- TKO vs RPRX Comparison
TKO vs RPRX Comparison
Compare TKO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- RPRX
- Stock Information
- Founded
- TKO 1980
- RPRX 1996
- Country
- TKO United States
- RPRX United States
- Employees
- TKO N/A
- RPRX N/A
- Industry
- TKO
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- RPRX Health Care
- Exchange
- TKO Nasdaq
- RPRX Nasdaq
- Market Cap
- TKO 14.5B
- RPRX 16.2B
- IPO Year
- TKO N/A
- RPRX 2020
- Fundamental
- Price
- TKO $184.25
- RPRX $39.23
- Analyst Decision
- TKO Strong Buy
- RPRX Strong Buy
- Analyst Count
- TKO 17
- RPRX 3
- Target Price
- TKO $213.69
- RPRX $46.00
- AVG Volume (30 Days)
- TKO 1.2M
- RPRX 3.9M
- Earning Date
- TKO 11-05-2025
- RPRX 11-05-2025
- Dividend Yield
- TKO 1.65%
- RPRX 2.25%
- EPS Growth
- TKO N/A
- RPRX N/A
- EPS
- TKO 1.85
- RPRX 1.75
- Revenue
- TKO $2,545,175,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- TKO $69.06
- RPRX $36.16
- Revenue Next Year
- TKO $27.63
- RPRX $2.04
- P/E Ratio
- TKO $99.24
- RPRX $22.36
- Revenue Growth
- TKO N/A
- RPRX 3.70
- 52 Week Low
- TKO $115.77
- RPRX $24.05
- 52 Week High
- TKO $212.49
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- TKO 44.33
- RPRX 59.26
- Support Level
- TKO $177.12
- RPRX $38.39
- Resistance Level
- TKO $187.01
- RPRX $40.01
- Average True Range (ATR)
- TKO 4.46
- RPRX 1.26
- MACD
- TKO -0.10
- RPRX 0.12
- Stochastic Oscillator
- TKO 50.20
- RPRX 63.19
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.